TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Moderna ( (MRNA) ).
On November 20, 2025, Moderna, Inc. announced updates on its pipeline progress and business strategy during its Analyst Day. This announcement is significant as it reflects the company’s ongoing efforts to advance its mRNA technology and strengthen its position in the biotechnology sector, potentially impacting stakeholders and market dynamics.
The most recent analyst rating on (MRNA) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Moderna stock, see the MRNA Stock Forecast page.
Spark’s Take on MRNA Stock
According to Spark, TipRanks’ AI Analyst, MRNA is a Neutral.
Moderna’s overall stock score reflects significant financial challenges, including declining revenues and profitability. Technical analysis indicates weak momentum, and valuation concerns persist with a negative P/E ratio. However, strategic cost reductions and partnerships provide some optimism for future growth.
To see Spark’s full report on MRNA stock, click here.
More about Moderna
Moderna, Inc. operates in the biotechnology industry, focusing on the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The company is known for its innovative approach to drug development, particularly in the field of infectious diseases, oncology, and rare diseases.
Average Trading Volume: 11,440,054
Technical Sentiment Signal: Sell
Current Market Cap: $9.45B
See more insights into MRNA stock on TipRanks’ Stock Analysis page.